Apr. 10, 2019

BIOSYSTEMS TECHNOLOGY, BIOVERSYS AND VOXCAN ANNOUNCE FUNDING BY EUROSTARS

BioSystems Technology, BioVersys and Voxcan announce funding for a total of about € 840’000, by Eurostars over a 3-year period for IMPACT2, a break-through innovative translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance.

Eurostars IMPACT2 PR 11.18